Paradigm Shift Therapeutics
Paradigm Shift Therapeutics, LLC (PSTx) was founded with a mission to develop transformational and affordable cancer therapies using a lean proof of concept approach. PSTx was launched in January 2014 by Teresa Burgess, Ph.D. and Kate Farrell, Ph.D. with an ongoing collaboration with Dr. David Roberts at the NCI focused on developing novel CD47-targeting inhibitors-a target with the potential to radically change cancer treatment. Thomas Miller, Ph.D. joined PSTx as a full partner in September 2014. The goal of our team is to develop inhibitors of CD47 that can be translated into clinical practice for treatment of patients with cancer.
7-day free trial · no credit card
Verified contacts
1
available on Kipplo
LinkedIn employees
4
1 to 10 range
Open roles
—
no listings
Distinct roles
1
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 1 verified contacts at Paradigm Shift Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
1 contacts with verified email or phone · masked until revealed.
No verified contacts on record for this company yet.
Top roles at Paradigm Shift Therapeutics
1 distinct titles indexed · top 1 shown.
- 1co-founder coo
Sign up to unlock all 1 contacts at Paradigm Shift Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 1 verified contacts at Paradigm Shift Therapeutics
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.